THE LEVELS OF PLASMINOGEN AND INHIBITOR OF PLASMINOGEN ACTIVATORS OF TYPE 1 IN ANTIPHOSPHOLIPID SYNDROME


Cite item

Full Text

Abstract

Aim. To estimate the levels of of plasminogen (Pg) and inhibitor of plasminogen activators of type 1 (IPA-1) in patients with antiphospholipid syndrome (APS) and to reveal correlations between their content and clinical-laboratory characteristics of APS. Material and methods. A Pg level was measured in 78 APS patients: 35 of them had systemic lupus erythematosus (SLE), 43 had primary APS and 19 with idiopathic thrombosis (IT). IPA-1 was detected in 63 APS patients: in 26, 37 and 18 patients, respectively. The control group consisted of 10 subjects free of autoimmune disease and thrombosis. The patients were matched by age. Pg and IPA-1 levels were estimated kinetically. The Pg level was stratified: normal (1.5-2.0 mcM, high (above 2.0 mcМ), low (under 1.5 mcM). Thromboses in the past occurred in 67 patients: arterial (n=32), venous (n=53), of combined localization (n=14). Results. Of 78 APS patients, Pg level was normal in 34 (44%), high in 20 (25%), low — in 24 (31%). Of 43 primary APS patients, low Pg was in 8 (19%), of 35 patients with SLE+APS — in 16 (46%) patients. A Pg concentration (1.59 [1.4; 1.98] mcM) was significantly less in APS patients with thrombosis than in patients with IT (2.4 [1.74; 2.99] mcM). Pg tended to lower levels than in the controls (1.95 [1.63; 2.26] mcM). IPA-1 varied in primary APS from 0.45 to > 1 nM, in SLE+APS from 0.44 to >1 nM, in IT —from 0.65 to 0.81 nM. The levels of active IPA-1 in all the patients with APS and IT were higher than in healthy donors and varied from 0.44 to >1 nM. Most of APS patients had high level of IPA-1 — 52 (83%) (IPA-1 from 0,1 to 1), of them 22 (85%) patients with SLE+APS and 30 (73%) — with primary APS. 11 (17%) APS patients had high IPA-1 ( >1), of them 4 (15%) with SLE+APS and 7 (27%) with primary APS. All IT patients had moderately high IPA-1 level. Conclusion. A low level of Pg in APS patients was seen significantly more frequently than in IT patients and controls and was associated with thrombosis, primarily arterial. Moderate high IPA-1 occurred in 83% of 63 APS patients, high in 17%. IT patients had moderately high IPA-1. High IPA-1 was associated in APS with thrombosis, primarily arterial.

About the authors

E V Ostryakova

Research Institute of Rheumatology

Email: katerina.ostryakova@yandex.ru
аспирант НИИР РАМН

T M Reshetnyak

Research Institute of Rheumatology

R B Aisina

M.V. Lomonosov State University

L I Mukhametova

M.V. Lomonosov State University

D A Gulin

M.V. Lomonosov State University

E N Alexandrova

Research Institute of Rheumatology

N V Seredavkina

Research Institute of Rheumatology

S D Varfolomeev

N.M. Emmanuel Institute of Biochemical Physics

A V Chernyakov

N.I. Pirogov Russian Medical University

Yu V Nikiforov

O.M. Filatov City hospital № 15

E L Nasonov

Research Institute of Rheumatology

References

  1. Насонов Е. Л. Антифосфолипидный синдром. М.: Литтерра; 2004.
  2. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M. A. Antiphospholipid syndrome. Lancet 2010; 376: 1498—1509.
  3. Mehdi A. A., Uthman I., Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur. J. Clin. Invest. 2010; 40: 451—464.
  4. Myakis S., Lockshin M. D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J. Thromb. Haemost. 2006; 4: 295—306.
  5. Решетняк Т. М., Вавилова Т. В. Клинико-лабораторные критерии диагностики антифосфолипидного синдрома — что нужно знать практическому врачу (лекция). Клин. лаб. диагн. 2010; 5: 12—22.
  6. Chen P. P., Giles I. Antibodies to serine proteases in the atiphospholipid syndrome. Curr. Rheumatol. Rep. 2010; 12: 45—52.
  7. Lisman T., de Groot P. G., Meijers J. C. M., Rosendaal F. R. Reduced plasma fibrinolytic potential is a risk factor foe venous thrombosis. Blood 2005; 105: 1102—1105.
  8. Smalberg J. H., Kruip M. J. H.A., Janssen H. L. A. et al. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis. Arterioscler. Thromb. Vas. Bol. 2011; 31: 485—493.
  9. Brandt J. T., Triplett D. A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoatulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant / Antiphospholipid Antibodies of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 1995; 74: 1185—1190.
  10. Brandt J. T., Barna L. K., Triplett D. A. Laboratory identification of lupus anticoaulants: results of the Second International Workshop for identification of lupus anticoagulants. Thromb. Haemost. 1995; 74: 1597—1603.
  11. Баркаган З. С., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза. М.: Ньюдиамед; 2001.
  12. Александрова Е. Н., Новиков А. А., Решетняк Т. М. и др. Диагностическое и прогностическое значение антител к кардиолипину, b2-гликопротеину-1 и протромбину при антифосфолипидном синдроме. Клинико-лаб. консилиум 2009; 2: 47—58.
  13. Левашов М. Ю., Айсина Р. Б., Гершкович К. Б., Варфоломеев С. Д. Механизм действия ω-аминокислот на активацию плазминогена и фибринолиз, инициированные стафилокиназой. Биохимия 2007; 72 (7): 872—882.
  14. Айсина Р. Б., Мухаметова Л. И., Гулин Д. А. и др. Ингибирующее действие ангиостатинов на активность системы плазминоген/активаторы плазминогена. Биохимия 2009; 74 (10): 1356—1367.
  15. Miles L. A., Plow E. F. Cellular regulation of fibrinolysis. Thromb. Haemost. 1991; 66: 32—36.
  16. Hajjar K. A. The molecular basis of fibrinolysis. In: Hematology of infancy and childhood. Philadelphia; 2003. 1497—1514.
  17. Долгов В. В., Свирин П. В. Лабораторная диагностика нарушений гемостаза. М.; Тверь: Триада; 2005.
  18. Cesarman-Maus G., Hajjar K. A. Molecular mechanisms of fibrinolysis. Br. J. Haematol. 2005; 129: 307—321.
  19. Hoover-Plow J. Does plasmin have anticoagulant activity? Vasc. Hlth Risk Manag. 2010; 6: 199—205.
  20. Pizzo S. V., Schwartz M. L., Hill R. L., McKee P.A. The effect of plasmin on the subunit structure of human fibrin. J. Biol. Chem. 1973; 248: 4574—4583.
  21. Hajjar K. A., Harpel P. C., Jaffe E. A., Nachman R. L. Binding of plasminogen to cultured human endothelial cells. J. Biol. Chem. 1986; 261: 11656—11662.
  22. Myöhänen H., Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell. Mol. Life Sci. 2004; 61: 2840—2858.
  23. Hoylaerts M., Rijken D. C., Lijnen H. R. et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J. Biol. Chem. 1982; 257: 2912—2929.
  24. Levin E. G., del Zoppo G. J. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am. J. Pathol. 1994; 144: 855—861.
  25. Saksela O. Plasminogen activation and regulation of proteolysis. Biochim. Biophys. Acta 1985; 823: 35—65.
  26. Binder B. R. Physiology and pathophysiology of the fibrinoliytic system. Fibrinolysis 1995; 9 (Suppl. 1): 3—8.
  27. Lijnen H. R., Zamarron C., Blaber M. et al. Activation of plasminogen by pro-urokinase. J. Biol. Chem. 1986; 261: 1253—1258.
  28. Sartori M. T., Simioni P., Patrassi G. M. et al. Combined heterozygous plasminogen deficiency and factor V leiden defect in the same kindred. Thromb. Hemost. 2000; 6 (1): 36—40.
  29. Bugge T. H., Flick M. J., Daugherty C. C., Degen J. L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes and Dev. 1995; 9: 794—807.
  30. Robbins K. C. Classification of abnormal plasmingens: dysplasminogenemias. Semin. Thromb. Haemost. 1990; 16: 217—220.
  31. Aoki N., Moroi M., Sakata Y. et al. Abnormal plasminogen: a hereditary molecular abnormality found in a patient with recurrent thrombosis. J. Clin. Invest. 1978; 61: 1186—1195.
  32. Sulzer I., Stucki B. Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members. Thromb. Haemost. 1998; 80 (1): 167—170.
  33. Tait R. C., Walker I. D., Conkie J. A. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thromb. Haemost 1996; 76 (6): 1004—1008.
  34. Zorio E., Gilabert-Estelles J., España F. et al. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 2008; 15: 923—929.
  35. Kohler H. P., Grant P. G. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 2000; 342: 1792—1801.
  36. Eren M., Painter C. A., Atkinson J. B. et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mise that express a stable form of human plasminogen-activator inhibitor-1. Circulation 2002; 106: 491—496.
  37. Sobel B. E., Woodcock-Mitchell J., Schneider D. J. et al. Increased plasminogen-activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation 1998; 97: 2213—2221.
  38. Kaitita K., Schoenhard J. A., Painter C. A. et al. Potential roles of plasminogen-activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibitor. J. Mol. Cell. Cardiol. 2002; 34: 617—627.
  39. Mottonen J., Strand A., Symersky J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270—273.
  40. Samad F., Yamamoto K., Loskutoff D. J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J. Clin. Invest. 1996; 97: 37—46.
  41. Forastiero R., Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. Curr. Rheumatol. Rev. 2005; 1: 177—187.
  42. Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008; 17: 872—877.
  43. Jurado M., Paramo J. A., Gutierrez-Pimentel M., Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other tissue disorders. Thromb. Haemost. 1992; 68: 516—520.
  44. Ames P. R. J., Tommasino C., Iannaccone L. et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic an-tiphosopholipid antibodies ? a crucial role for acquired free protein S deficiency. Thromb. Haemost. 1996; 75: 190—194.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies